ARDS Aridis Pharmaceuticals

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersSigilon Therapeutics (NASDAQ:SGTX) stock moved upwards by 64.8% to $1.16 during Tuesday's regular session. The current volume of 4.3 million shares is 1447.6% of Sigilon Therapeutics's average

03-15 01:35

Stocks That Hit 52-Week Lows On Tuesday

 Tuesday's morning session saw 84 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was CVS Health (NYSE:CVS)

03-15 01:30

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers Ainos, Inc. (NASDAQ:AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a strat

03-15 01:08

Aridis Pharmaceuticals Shares Are Trading Lower After the Company Announced a $2.28 Million Registered Direct Offering.

Aridis Pharmaceuticals shares are trading lower after the company announced a $2.28 million registered direct offering.

03-14 22:38

Aridis Pharmaceuticals Shares Tumble After Stock Offering >ARDS

By Colin Kellaher Shares of Aridis Pharmaceuticals Inc. slid more than 20% on Tuesday after the biopharmaceutical company said it was raising $2.28 million in a dilutive registered direct stock offer

03-14 22:37

Aridis Pharmaceuticals Announces $2.28M Offering

Aridis Pharmaceuticals Announces $2.28M Offering

03-14 21:46

Aridis Pharmaceuticals Says On March 10 Co. Received Notice From Nasdaq Indicating Bid Price For Co.'s Common Stock For Last 30 Consecutive Business Days Had Closed Below Minimum $1.00/Share

Aridis Pharmaceuticals Says On March 10 Co. Received Notice From Nasdaq Indicating Bid Price For Co.'s Common Stock For Last 30 Consecutive Business Days Had Closed Below Minimum $1.00/Share

03-14 04:13

Aridis Pharmaceuticals Says Phase 2a Cystic Fibrosis Trial Meets Targets; Shares Jump

10:35 AM EDT, 03/13/2023 (MT Newswires) -- Aridis Pharmaceuticals (ARDS) said Monday that preliminary top-line data from its phase 2a trial of AR-501 in people with cystic fibrosis showed that the pri

03-13 22:41

Aridis Stock Surges ~35% as Lung Disease Drug AR-501 Meets Main Goal in Mid-stage Study

03-13 21:48

Why Aridis Pharmaceuticals Shares Are Soaring Today

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and ot

03-13 21:15